Loading filters...
Publications per Year (880 total)
1
·
1
·
3
·
2
·
8
·
5
2000
8
·
9
·
10
·
8
·
12
2005
21
·
15
·
24
·
28
·
22
2010
18
·
26
·
34
·
22
·
30
2015
30
·
37
·
38
·
36
·
63
2020
77
·
55
·
61
·
70
·
72
2025
34
·
Loaded
Click to load
50 / 880 papers loaded(scroll for more)
202630 papers
Generalearly2026
Impact of Positive Resection Margins on Recurrence and Survival After Resection and Adjuvant Chemotherapy in Pancreatic Cancer: Results of the PRODIGE 24-CCTG PA-6 Randomized Controlled Trial.
Lambert A et al. Ann Surg. 2026
Generalearly2026
Neoadjuvant Oxaliplatin and Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: CT Features of Chemotherapy-Associated Liver Injury and Postoperative Complications.
Tessier F et al. Ann Surg Oncol. 2026
MSI-H/dMMRAll Stages2026
Minimal Residual Disease Assessment Through ctDNA Facilitates Tailored Immunotherapy in MSI-High, NTRK1-Fusion Pancreatic Adenocarcinoma.
Rohlfing S et al. Oncologist. 2026
Generaladvanced2026
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Wainberg ZA et al. Nat Med. 2026
BRCA/HRDadvanced2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.
Park W et al. Nat Med. 2026
Generaladvanced2026
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.
Procaccio L et al. Oncologist. 2026
GeneralAll Stages2026
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.
Alagesan B et al. Clin Cancer Res. 2026
Generalearly2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.
Willems RAL et al. J Clin Oncol. 2026
KRAS mutantAll Stages2026
Emerging landscape of KRAS inhibitors in cancer treatment.
Riedl JM et al. Cancer Cell. 2026
GeneralAll Stages2026
Optimal Time Between Completion of Preoperative Chemotherapy and Surgery for Locally Advanced Pancreatic Cancer.
Cathomas M et al. Ann Surg Oncol. 2026
GeneralAll Stages2026
Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy.
Bouchart C et al. Br J Cancer. 2026
Generalearly2026
Clinical Significance of an R1 Resection for Pancreatic Ductal Adenocarcinomas Treated by Intensive FOLFIRINOX Induction-Based Chemotherapy and Extended Pancreatectomies.
Addeo P et al. Ann Surg Oncol. 2026
Generalearly2026
Surgery for Locally Advanced Pancreatic Cancer: Oncological Landmarks for Venous and Arterial Reconstruction.
Palen A et al. Ann Surg Oncol. 2026
Generalearly2026
A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Suto H et al. Ann Surg Oncol. 2026
Generaladvanced2026
Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxel.
Kan T et al. Int J Cancer. 2026
BRCA/HRDAll Stages2026
Precision oncology promise in the management of pancreatic acinar cell carcinoma.
Baskar S et al. Eur J Cancer. 2026
Generaladvanced2026
Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring.
Ni J et al. Clin Cancer Res. 2026
BRCA/HRDadvanced2026
Targeting the ATM-TGS1-BRCA1 Axis Overcomes Genotoxic Therapy Resistance in Pancreatic Adenocarcinoma.
Li C et al. Cancer Res. 2026
Generaladvanced2026
Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.
Yasuda S et al. Ann Surg. 2026
GeneralAll Stages2026
Inframesocolic Artery-First Approach with SMA Divestment to Confirm Resectability in Minimally Invasive Modified Appleby Procedure.
Blanco N et al. Ann Surg Oncol. 2026
Generalearly2026
Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observational Study.
Zou S et al. Pancreas. 2026
GeneralAll Stages2026
Convergence for Inactivation of TGF-β Signaling Is a Common Feature of Advanced Pancreatic Cancer.
Hong J et al. Cancer Discov. 2026
Generalearly2026
Relative Dose Intensity and Outcomes in Elderly Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy.
Takeda T et al. J Hepatobiliary Pancreat Sci. 2026
KRAS mutantAll Stages2026
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.
Long SA et al. Cancer Res. 2026
Generaladvanced2026
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial.
Macarulla T et al. ESMO Open. 2026
Generaladvanced2026
SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217).
Chiang NJ et al. Eur J Cancer. 2026
Generaladvanced2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer.
Hendifar AE et al. J Clin Oncol. 2026
GeneralAll Stages2026
Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial.
Rompen IF et al. Ann Surg. 2026
GeneralAll Stages2026
Stapled Wedge Resection of the Portal Vein/Superior Mesenteric Vein During Robotic Pancreaticoduodenectomy: Feasibility and Short-term Outcomes.
Imamura T et al. Ann Surg Oncol. 2026
Generalearly2026
Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma.
Andel PCM et al. Ann Surg Oncol. 2026
202520 papers
Generalearly2025
Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX.
Stoop TF et al. JAMA Oncol. 2025
Generalearly2025
Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resection After Preoperative Chemoradiotherapy.
Hayasaki A et al. Pancreas. 2025
Generalearly2025
Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreatic Cancer.
Yun WG et al. Ann Surg Oncol. 2025
Generaladvanced2025
Total Pancreatectomy for Locally Advanced Pancreatic Adenocarcinoma with Coeliac Trunk Resection and Retrograde Gastric Revascularization Through Aorto-Hepato-Spleno Allograft.
Touzmanian J et al. Ann Surg Oncol. 2025
Generalearly2025
Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter TONO Study.
Addeo P et al. Ann Surg Oncol. 2025
Generalearly2025
High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1.
Fujita K et al. Ann Surg Oncol. 2025
Generalearly2025
Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX.
Rompen IF et al. Ann Surg. 2025
Generalearly2025
Robotic Distal Pancreatectomy with Celiac Axis Resection and SMA Divestment: A Step-by-Step Educational Video.
Garnier J et al. Ann Surg Oncol. 2025
Generalearly2025
Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Multicenter Analysis.
Hays SB et al. Ann Surg Oncol. 2025
Generaladvanced2025
Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection.
Blair AB et al. Ann Surg Oncol. 2025
Generaladvanced2025
Pancreatoduodenectomy with En Bloc Superior Mesenteric Artery and Vein Resection Under Temporary Mesenterico-Portal Venous Shunt: The Strasbourg Technique.
Bachellier P et al. Ann Surg Oncol. 2025
Generaladvanced2025
Technique of Circumferential Divestment of the Superior Mesenteric Artery for Locally Advanced Pancreatic Cancer.
Ono Y et al. Ann Surg Oncol. 2025
Generalearly2025
The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study.
Rangelova E et al. Ann Oncol. 2025
GeneralAll Stages2025
Robotic Pancreatoduodenectomy with Segmental Portomesenteric Venous Resection and Primary End-to-End Reconstruction: Approach to a Tension-Free Anastomosis.
Fong ZV et al. Ann Surg Oncol. 2025
Generalearly2025
Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study.
Cohen DJ et al. Oncologist. 2025
Generalearly2025
Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Usefulness and Limitations.
Choi GW et al. Ann Surg Oncol. 2025
GeneralAll Stages2025
Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer.
Grierson PM et al. Clin Cancer Res. 2025
Generalearly2025
Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy.
Omiya K et al. Ann Surg Oncol. 2025
Generalearly2025
Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study.
Stoop TF et al. Br J Cancer. 2025
GeneralAll Stages2025
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study).
Schwarz L et al. J Clin Oncol. 2025